Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson’s disease

✍ Scribed by F. Blandini; G. Nappi; R. Fancellu; A. Mangiagalli; A. Samuele; G. Riboldazzi; D. Calandrella; C. Pacchetti; G. Bono; E. Martignoni

• Publisher: Springer
• Year: 2003
• Tongue: English
• Weight: 336 KB
• Volume: 110
• Category: Article
• ISSN: 1435-1463
• DOI: 10.1007/s00702-003-0004-z